Plowman et al., Receptor tyrosine kinases as targets for drug intervention, DN&P 7(6):334-339, Aug. 1994.* |
Davis-Smyth et al., The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction cascade, EMBO J., 15(18): 4919-27, Sep. 1996.* |
Aiello et al., “Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins” Proc Natl. Acad. Sci. 92:10457-10461 (1995). |
Boocock, et al., “Expression of Vascular Endothelial Growth Factor and Its Receptors flt and KDR in Ovarian Carcinoma” Journal of the National Cancer Institute, 87:506-516 1995. |
Brown et al., “Expressions of Vascular Permeability Factor (Vascular Endothelial Growth Factor) and Its Receptors in Adenocarcinomas of the Gastrointestinal Tract1” Cancer Research 53:4727-4735 (1993). |
Capon et al., “Designing CD4 immunoadhesins for AIDS therapy” Nature 337:525-531 (1989). |
Dvorak et al., “Distribution of Vascular Permeability Factor (Vascular Endothelial Growth Factor) in Tumors: Concentration in Tumor Blood Vessels” J. Exp. Med. 174:1275-1278 (1991). |
Flores et al., “Angiogenesis: an update” Histol Histopath 9:807-843 (1994). |
Folkman “What is the Evidence that Tumors Are Angiogenesis Dependent?” Journal of the National Cancer Institute, 82:4-6 (1990). |
Gengrinovitch et al., “Platelet Factor-4 Inhibits the Mitogenic Activity of VEGF121 and VEGF165 Using Several Concurrent Mechanisms” The Journal of Biological Chemistry, 270:15059-15065 (1995). |
Kendall et al., “Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor” Proc. Natl. Acad. Sci. 90:10705-10709 (1993). |
Kendall et al., “Specificity of Vascular Endothelial Cell Growth Factor Receptor Ligand Binding Domains” Biochemical & Biophysical Research Communications, 201:326-330 (1994). |
Kim et al., “Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo” Nature, 362:841-844 (1993). |
King et al., “Expression, purification and characterization of a mouse-human chimeric antibody and chimeric Fab' fragment” Biochem Journal, 281:317-323 (1992). |
Kondo et al., “Signigicance of Vascular Endothelial Growth Factor/Vascular Permeability Factor for Solid Tumor Growth, and Its Inhibition by the Antibody” Biochemical & Biophysical Res. Com. 194:1234-1241 (1993). |
Lane et al., Radioimmunotherapy of metastatic colorectal tumours with iodine-131-labelled antibody to carcinoembryonic antigen: phase I/II study with comparative biodistribution of intact and f(ab)2 antibodies British Journal of Cancer, 70:521-525 1994. |